Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Koichi Uesaka is active.

Publication


Featured researches published by Koichi Uesaka.


World Journal of Hepatology | 2010

Twenty four-week peginterferon plus ribavirin after interferon-β induction for genotype 1b chronic hepatitis C

Hiroaki Okushin; Kazuhiko Morii; Koichi Uesaka; Shiro Yuasa

AIM To investigate the possibility of shortening the duration of peginterferon (Peg-IFN) plus ribavirin (RBV) combination therapy by incorporating interferon-β (IFN-β) induction therapy. METHODS A one treatment arm, cohort prospective study was conducted on seventy one patients. The patients were Japanese adults with genotype 1b chronic hepatitis C, HCV-RNA levels of ≥ 5.0 Log IU/mL or 100 KIU/mL, and platelet counts of ≥ 90 000/μL. The treatment regimen consisted of a 2 wk course of twice-daily administration of IFN-β followed by 24 wk Peg-IFN plus RBV combination therapy. We prolonged the duration of the Peg-IFN plus RBV therapy to 48 wk if the patient requested it. RESULTS The patients, including 44% males, were characterized by an median age of 63 years (range: 32-78 years), an median platelet count of 13.9 (range: 9.1-30.6) × 10(4)/μL, 62% IFN-naïve, and median HCV-RNA of 6.1 (range: 5.1-7.2) Log IU/mL. The sustained virologic response (SVR) rates were 34% (Peg-IFN: 1-24 wk, n = 61, 95% confidence interval (CI): 24%-47%) and 55% (Peg-IFN: 20-24 wk, n = 31, 95% CI: 38%-71%, P < 0.001; vs Peg-IFN: 1-19 wk). The SVR rate when the administration was discontinued early was 13% (Peg-IFN: 1-19 wk, n = 30, 95% CI: 5%-30%), and that when the administration was prolonged was 50% (Peg-IFN: 25-48 wk, n = 10, 95% CI: 24%-76%, P < 0.05; vs Peg-IFN: 1-19 wk). In the patients who received 20-24 wk of Peg-IFN plus RBV, only the higher platelet count (≥ 130 000/μL) was significantly correlated with the SVR (odds ratio: 11.680, 95% CI: 2.3064-79.474, P = 0.0024). In 45% (14/31) of the patients with a higher platelet count (≥ 130 000/μL) before therapy, the HCV-RNA level decreased to below 3.3 Log IU/mL at the completion of IFN-β, and their SVR rate was 93% (13/14) after 20-24 wk administration of Peg-IFN plus RBV. CONCLUSION These results suggest the possibilities of shortening the duration of Peg-IFN plus RBV combination therapy by actively reducing HCV-RNA levels using the IFN-β induction regimen.


Journal of Infection and Chemotherapy | 2013

Factors that make it difficult to diagnose cervical tuberculous lymphadenitis

Tomoyasu Tachibana; Yorihisa Orita; Masayoshi Fujisawa; Michihiro Nakada; Yuya Ogawara; Yuko Matsuyama; Iku Abe; Yasuharu Sato; Koichi Uesaka; Kazunori Nishizaki

Cervical tuberculous lymphadenitis is mainly diagnosed by analyzing tissue samples obtained by fine-needle aspiration (FNA). However, some cases remain diagnostic challenges even after polymerase chain reaction analysis of FNA specimens. To delineate differences between cases that are relatively easy to diagnose and those for which diagnosis is difficult, 22 patients with cervical tuberculous lymphadenitis were studied retrospectively. FNA tissues were used to diagnose 14 cases (group A), whereas excisional biopsy was required for accurate diagnosis of 8 cases (group B). These two groups were compared with regard to results of blood examinations, ultrasound appearance, and various other procedures required to reach the final diagnosis. The results indicated that diagnosis of cervical tuberculous lymphadenitis was more difficult for patients with lower white blood cell counts, lower serum C-reactive protein levels, and absence of lymph node fusion or abscess formation on ultrasonography. The possibility of tuberculosis as a cause of cervical lymphadenopathy should always be considered, even when the presenting symptoms are not typical of this disease.


Clinical Journal of Gastroenterology | 2012

Mesenteric panniculitis presenting as liver dysfunction

Kazuhiko Morii; Tomoko Hatono; Hiroaki Okushin; Takanori Watanabe; Shiso Sato; Koichi Uesaka; Shiro Yuasa

Mesenteric panniculitis is a non-specific inflammatory disorder affecting adipose tissues of the mesentery. Mesenteric adipose tissues contain macrophages and other inflammatory cells, which may secrete tumor necrosis factor α, interleukin (IL)-1, and IL-6. These cytokines collect into the portal vein and thereby flow into the liver, possibly influencing hepatic function. Mesenteric panniculitis often occurs with inflammatory reactions such as fever and elevated erythrocyte sedimentation rates. Systemic inflammatory disorders can evoke acute cholestatic liver involvement, which is mediated by proinflammatory cytokines. However, no reports have focused on the association between mesenteric panniculitis and liver involvement. We report a rare case of mesenteric panniculitis presenting as liver dysfunction. Immunohistochemical staining of the liver demonstrated a marked decrease in expression of canalicular transport systems. These findings indicated cholestatic liver dysfunction associated with mesenteric panniculitis.


Clinical Journal of Gastroenterology | 2012

Successful hepatectomy for intraperitoneal rupture of pyogenic liver abscess caused by Klebsiella pneumoniae

Kazuhiko Morii; Asako Kashihara; Sho Miura; Hiroaki Okuhin; Takanori Watanabe; Shiso Sato; Koichi Uesaka; Shiro Yuasa

Klebsiella pneumoniae (KP) is the most common cause of pyogenic liver abscess in eastern Asia. KP liver abscess commonly presents as a single large abscess with a predominantly solid consistency. It is sometimes unsuitable for percutaneous catheter drainage because of the poorly liquefied contents. Antibiotic therapy alone may raise a probability of treatment failure and occurrence of complications such as abscess rupture. Hepatic or portal venous thrombosis, hematogenous spread, and spontaneous rupture also occur frequently. We report a case of KP liver abscess with a typical solid appearance, complicated by disseminated intravascular coagulation, spontaneous rupture, and pyogenic spondylitis.


Hepatology Research | 2014

Indices of initial hepatitis C virus RNA reduction rate to predict efficacy of interferon-beta followed by peginterferon plus ribavirin for genotype 1b high viral load.

Hiroaki Okushin; Takeharu Yamamoto; Hiroshi Kishida; Kazuhiko Morii; Koichi Uesaka

Initial hepatitis C virus (HCV) RNA reduction was investigated as a potential index for sustained virological response (SVR) in the treatment of interferon (IFN)‐β followed by peginterferon plus ribavirin (PEG IFN/RBV).


World Journal of Gastroenterology | 2008

Short-term intravenous interferon therapy for chronic hepatitis B.

Hiroaki Okushin; Toru Ohnishi; Kazuhiko Morii; Koichi Uesaka; Shiro Yuasa


World Journal of Gastroenterology | 2006

Pyogenic liver abscess after choledochoduodenostomy for biliary obstruction caused by autoimmune pancreatitis.

Nobuyuki Toshikuni; Kyohei Kai; Shizo Sato; Motoko Kitano; Masayoshi Fujisawa; Hiroaki Okushin; Kazuhiko Morii; Shinjiro Takagi; Masahiro Takatani; Hirofumi Morishita; Koichi Uesaka; Shiro Yuasa


International Journal of Infectious Diseases | 2014

Reversible splenial lesion of the corpus callosum associated with bacterial meningitis

Kazuhiko Morii; Yuya Kogita; Miho Takata; Takeharu Yamamoto; Hiroshi Kishida; Hiroaki Okushin; Koichi Uesaka


Esophagus | 2015

Diffuse large B-cell lymphoma of the thyroid which caused esophageal fistula

Tomoyasu Tachibana; Yorihisa Orita; Masayoshi Fujisawa; Yasushi Hiramatsu; Yuya Ogawara; Yuko Matsuyama; Iku Abe; Kaori Uchino; Hirofumi Morishita; Tetsuji Nobuhisa; Koichi Uesaka; Kazunori Nishizaki


Journal of gastroenterology and hepatology research | 2012

Fibrosing Cholestatic Hepatitis C in a Patient with Systemic Lupus Erythematosus

Kazuhiko Morii; Takefumi Yamamoto; Tomoko Hatono; Misako Yokoyama; Masayasu Omori; Miho Takata; Mariko Tsuchida; Satoshi Fujisawa; Ryutaro Yamanaka; Hidetoshi Kagawa; Kaori Uchino; Masayoshi Fujisawa; Hiroaki Okushin; Koichi Uesaka; Shiro Yuasa

Collaboration


Dive into the Koichi Uesaka's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge